Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mia‐Lisa Zischinsky"'
Autor:
Shixian Yan, Paul Curtis Schöpe, Joe Lewis, Kerstin Putzker, Ulrike Uhrig, Edgar Specker, Jens Peter von Kries, Peter Lindemann, Anahid Omran, Hector E. Sanchez-Ibarra, Anke Unger, Mia-Lisa Zischinsky, Bert Klebl, Wolfgang Walther, Marc Nazaré, Dennis Kobelt, Ulrike Stein
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115698- (2023)
Metastasis is directly linked to poor prognosis of cancer patients and warrants search for effective anti-metastatic drugs. MACC1 is a causal key molecule for metastasis. High MACC1 expression is prognostic for metastasis and poor survival. Here, we
Externí odkaz:
https://doaj.org/article/6858c7b995054e39a758cb5c3e16c24a
Autor:
Magdalena Keller, Katharina Rohlf, Annika Glotzbach, Gregor Leonhardt, Simon Lüke, Katharina Derksen, Özlem Demirci, Defne Göçener, Mohammad AlWahsh, Jörg Lambert, Cecilia Lindskog, Marcus Schmidt, Walburgis Brenner, Matthias Baumann, Eldar Zent, Mia-Lisa Zischinsky, Birte Hellwig, Katrin Madjar, Jörg Rahnenführer, Nina Overbeck, Jörg Reinders, Cristina Cadenas, Jan G. Hengstler, Karolina Edlund, Rosemarie Marchan
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-18 (2023)
Abstract Background Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore, the identification o
Externí odkaz:
https://doaj.org/article/3ce2fcec0f4f49f29458097699d65efb
Autor:
Magdalena Keller, Katharina Rohlf, Annika Glotzbach, Gregor Leonhardt, Simon Lüke, Katharina Derksen, Özlem Demirci, Defne Göçener, Mohammad AlWahsh, Jörg Lambert, Cecilia Lindskog, Marcus Schmidt, Walburgis Brenner, Matthias Baumann, Eldar Zent, Mia-Lisa Zischinsky, Birte Hellwig, Katrin Madjar, Jörg Rahnenführer, Nina Overbeck, Jörg Reinders, Cristina Cadenas, Jan G. Hengstler, Karolina Edlund, Rosemarie Marchan
Background Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore, the identification of new tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb26b2668a830456c8cb4cc3358031b
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-496265
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-496265
Autor:
Mohammad Akbarzadeh, Jana Flegel, Sumersing Patil, Erchang Shang, Rishikesh Narayan, Marcel Buchholzer, Neda S. Kazemein Jasemi, Michael Grigalunas, Adrian Krzyzanowski, Daniel Abegg, Anton Shuster, Marco Potowski, Hacer Karatas, George Karageorgis, Niloufar Mosaddeghzadeh, Mia‐Lisa Zischinsky, Christian Merten, Christopher Golz, Lucas Brieger, Carsten Strohmann, Andrey P. Antonchick, Petra Janning, Alexander Adibekian, Roger S. Goody, Mohammad Reza Ahmadian, Slava Ziegler, Herbert Waldmann
Publikováno v:
Angewandte Chemie International Edition. 61
For the discovery of novel chemical matter generally endowed with bioactivity, strategies may be particularly efficient that combine previous insight about biological relevance, e.g., natural product (NP) structure, with methods that enable efficient
Autor:
Paul Curtis Schöpe, Shixian Yan, Dennis Kobelt, Joe Lewis, Kerstin Putzker, Ulrike Uhrig, Edgar Specker, Jens Peter von Kries, Mathias Dahlmann, Hector E Sanchez-Ibarra, Anke Unger, Mia-Lisa Zischinsky, Bert Klebl, Peter Lindemann, Wolfgang Walther, Marc Nazaré, Ulrike Stein
Publikováno v:
Cancer Research. 83:A039-A039
The leading cause of cancer related deaths is the formation of metastasis, frequently caused by insufficient therapies and limited therapy options. Novel compounds able to interfere with metastasis formation are therefore of tremendous interest. Colo
Autor:
Bert Klebl, Slava Ziegler, Stephanie A. Ketcham, Axel Choidas, Hans R. Schöler, Matthias Baumann, Michael Glatza, Ting-Yu Yeh, Lydia Reinhardt, Herbert Waldmann, Jared Sterneckert, Peter Reinhardt, Philipp Küchler, Masin Abo-Rady, Gunther Zischinsky, Swaran Nandini, Peter Habenberger, Susanne Höing, Stephen J. King, Trina A. Schroer, Mia-Lisa Zischinsky, Hannes C.A. Drexler, Lea Kremer, Nancy E. Martinez, Aaron P. Ledray, Peter Nussbaumer
Publikováno v:
Cell Chem Biol
Summary Aberrant hedgehog (Hh) signaling contributes to the pathogenesis of multiple cancers. Available inhibitors target Smoothened (Smo), which can acquire mutations causing drug resistance. Thus, compounds that inhibit Hh signaling downstream of S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee2b34bf7961e88796ba78e05ec756a
https://europepmc.org/articles/PMC8543760/
https://europepmc.org/articles/PMC8543760/
Autor:
Bert Klebl, Philipp Küchler, Peter Reinhardt, Hans R. Schöler, Lea Kremer, Trina A. Schroer, Lydia Wagner, Matthias Baumann, Stephanie A. Ketcham, Gunther Zischinsky, Axel Choidas, Hannes C.A. Drexler, Ting-Yu Yeh, Herbert Waldmann, Jared Sterneckert, Slava Ziegler, Nancy E. Martinez, Peter Nussbaumer, Peter Habenberger, Mia-Lisa Zischinsky, Susanne Höing
Publikováno v:
Cancer Research. 76:2997-2997
Introduction: Aberrant hedgehog (Hh) pathway activation contributes to the pathogenesis of multiple cancers. Currently available Hh pathway inhibitors target Smoothened (Smo) which can acquire mutations causing drug resistance. Therefore, a major cha